This page identifies priority research areas for neurodegenerative disease R&D, focusing on therapeutic targets, mechanistic pathways, and strategic investment opportunities. The analysis considers disease burden, scientific tractability, and commercial potential.
This page identifies priority research areas based on gap analysis of the current clinical trial landscape across neurodegenerative diseases. Analysis of ClinicalTrials.gov data reveals significant unmet needs and investment opportunities. [1]
| Disease | Total Trials | Active Trials | Late-Stage (Phase 3/4) | Biomarker Programs | Investment Landscape |
|---|---|---|---|---|---|
| Alzheimer's Disease | 4,910 | 1,208 (24.6%) | 489 (10.0%) | 453 (9.2%) | View |
| Parkinson's Disease | 4,613 | 1,061 (23.0%) | 437 (9.5%) | 254 (5.5%) | View |
| Amyotrophic Lateral Sclerosis | 1,569 | 434 (27.7%) | 91 (5.8%) | 124 (7.9%) | View |
| Frontotemporal Dementia | 380 | 124 (32.6%) | 20 (5.3%) | ~30 (7.9%) | View |
| Huntington's Disease | 285 | 66 (23.2%) | 25 (8.8%) | ~20 (7.0%) | View |
Data refreshed: 2026-03-17
The complete absence of combination-therapy signals in major neurodegenerative disease trials represents a critical gap. Given the multifactorial nature of these diseases, addressing multiple pathological mechanisms simultaneously is likely necessary for disease modification. [2]
Only 5-9% of current trials incorporate biomarker endpoints, limiting the ability to demonstrate biological activity and select responsive patient populations. [3]
Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Huntington's disease collectively affect ~100,000-200,000 patients in the US but have minimal trial activity. [4]
| Disease | Estimated US Prevalence | Active Trials |
|---|---|---|
| Huntington's Disease | ~30,000 | 66 |
| MSA | ~50,000 | ~30 |
| PSP | ~20,000 | ~25 |
| CBD | ~5,000 | ~15 |
Parkinson's disease has robust motor symptom coverage but significant gaps in non-motor symptom therapeutics, which often have greater impact on quality of life. [5]
ALS has the lowest late-stage representation (5.8%) and smallest overall pipeline, despite being uniformly fatal with median survival of 2-5 years. [6]
Neuroinflammation is a common feature across all neurodegenerative diseases but remains undertargeted in clinical trials. [7]
Genetic forms of neurodegenerative diseases offer well-validated targets with clear mechanisms. [8]
| Gene | Associated Diseases | Therapeutic Approach |
|---|---|---|
| GBA1 | Parkinson's, Lewy Body Dementia | Gene augmentation, enzyme enhancement |
| LRRK2 | Parkinson's | Kinase inhibitors, gene silencing |
| SNCA | Parkinson's, MSA | Alpha-synuclein aggregation inhibitors, gene silencing |
| MAPT | FTD, Alzheimer's | Tau aggregation inhibitors |
| C9orf72 | ALS, FTD | Gene silencing, dipeptide repeat inhibitors |
| HTT | Huntington's | ASO, RNAi gene silencing |
The neurodegenerative disease R&D landscape shows significant gaps in combination therapies, biomarker integration, rare disease research, and non-motor symptom treatment. Addressing these priorities requires coordinated effort across academic, industry, and regulatory stakeholders. The highest-impact investments in the near term would be:
For current clinical trials across neurodegenerative diseases, see:
ClinicalTrials.gov Neurodegenerative Disease Pipeline Analysis (2026). 2026. ↩︎
Combination Therapy Approaches in Alzheimer's Disease - Nature Reviews Drug Discovery (2024). 2024. ↩︎
Blood-Based Biomarkers for Neurodegenerative Diseases - Acta Neuropathologica (2025). 2025. ↩︎
Rare Neurodegenerative Disease Epidemiology - Orphanet Journal of Rare Diseases (2024). 2024. ↩︎
[Parkinson's Disease Non-Motor Symptoms - Lancet Neurology (2024)](https://doi.org/10.1016/S1474-4422(24). 2024. ↩︎
ALS Clinical Trials Landscape - Nature Reviews Neurology (2025). 2025. ↩︎
Neuroinflammation in Neurodegeneration - Neuron (2024). 2024. ↩︎
Genetic Forms of Neurodegenerative Diseases - Brain (2025). 2025. ↩︎